Ulka N. Vaishampayan, MBBS, FAB, discusses the potential of tivozanib in advanced renal cell carcinoma.
Ulka N. Vaishampayan, MBBS, FAB, director of the Phase I program at the Rogel Cancer Center and a professor of internal medicine at the University of Michigan, discusses the potential of tivozanib (Fotivda) in advanced renal cell carcinoma (RCC).
At present, tivozanib is not approved for use in the United States for patients with advanced RCC, although it has been approved in Europe; it is used as a single-agent VEGF TKI in this patient population, says Vaishampayan. In the United States, given the results of the phase 3 TIVO-3 trial, tivozanib could be a reasonable third-line option to consider for patients who have already received both VEGF TKI and immune-based regimens, adds Vaishampayan.
Tivozanib appears to prolong progressing-free survival, is relatively well-tolerated, and may provide patients with an additional efficacy benefit in the pretreated setting, concludes Vaishampayan.